Oncoology Drugs Market Global Report 2017
Including: Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Non-Small Cell Lung Cancer, Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Cancer, Cervical Cancer, Blood Cancer, Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document.

**We look forward to being of service to you.**

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

**Phone:** +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk

Increase in usage of biotechnological technologies in the development of anticancer drugs such as immunotherapies or monoclonal antibodies, adoptive-cell therapies, and new vaccines is an emerging trend in this market. Major competitors such as Roche, Eli Lilly, Genentech, Pfizer, and Biogen Idec are focusing on the R&D of new technologies such as next generation sequencing to develop MABs that are used for the development of chronic diseases such as cancer and other chronic diseases.

The Oncology Drugs Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global oncology drugs sector.

Reasons to Purchase

• Outperform competitors using accurate up to date demand-side dynamics information.
• Identify growth segments for investment.
• Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
• Create regional and country strategies on the basis of local data and analysis.
• Stay abreast of the latest customer and market research findings
• Benchmark performance against key competitors.
• Develop strategies based on likely future developments.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Gain a global perspective on the development of the market.
• Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Description:

Where is the largest and fastest growing market for the oncology drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The
oncology drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical drugs market, and compares it with other markets.

• The market characteristics section of the report defines and explains the market.

• The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

• Market segmentations break down market into sub markets.

• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.

• Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

• The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.

• The oncology drugs market section of the report gives context. It compares the oncology drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The Oncology Drugs Indicators Comparison.

• The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.

Scope


Companies Mentioned: F. Hoffmann-La Roche Ltd, Novartis AG, Celgene, Johnson & Johnson, and Bristol-Myers Squibb Company

Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa

Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Oncology Drugs Indicators Comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Additional Details

**Publisher**: The Business Research Company  
**Reference**: 2101  
**Number of Pages**: 125  
**Report Format**: PDF  
**Publisher Information**:  

The Business Research Company excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

The Business Research Company’s Consultants have qualifications from top institutes which include MBAs, MSCs, MDs, CFAs and CAs. The Business Research Company’s consultants gain training and qualifications from the Market Research Society and are trained in advanced research practices, techniques, and ethics.

Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 10.3.5. China Oncology Drugs Percentage Of GDP, 2012 - 2020; 10.3.6. China Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 10.4. India Oncology Drugs Market; 10.4.1. India Oncology Drugs Market Overview; 10.4.2. India Oncology Drugs Forecast Market, 2012 - 2016; 10.4.3. India Oncology Drugs Forecast Market, 2016 - 2020; 10.4.4. India Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 10.4.5. India Oncology Drugs Percentage Of GDP, 2012 - 2020; 10.4.6. India Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 10.5. Japan Oncology Drugs Market; 10.5.1. Japan Oncology Drugs Market Overview; 10.5.2. Japan Oncology Drugs Historic Market, 2012 - 2016; 10.5.3. Japan Oncology Drugs Forecast Market, 2016 - 2020; 10.5.4. Japan Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 10.5.5. Japan Oncology Drugs Percentage Of GDP, 2012 - 2020; 10.5.6. Japan Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 10.6. Australia Oncology Drugs Market; 10.6.1. Australia Oncology Drugs Market Overview; 10.6.2. Australia Oncology Drugs Historic Market, 2012 - 2016; 10.6.3. Australia Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11. Western Europe Oncology Drugs Market: Country Analysis; 11.1. Western Europe Oncology Drugs Market Overview; 11.1.1. Western Europe Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.2. Western Europe Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.3. UK Oncology Drugs Market; 11.3.1. UK Oncology Drugs Market Overview; 11.3.2. UK Oncology Drugs Forecast Market, 2016 - 2020; 11.3.3. UK Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.4. Germany Oncology Drugs Market; 11.4.1. Germany Oncology Drugs Forecast Market, 2012 - 2016; 11.4.2. Germany Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.4.4 Germany Oncology Drugs Percentage Of GDP, 2012 - 2020; 11.4.5 Germany Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 11.5 France Oncology Drugs Market; 11.5.1 France Oncology Drugs Market, 2012 - 2016; 11.5.2 France Oncology Drugs Market, 2016 - 2020; 11.5.3 France Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.5.5 France Oncology Drugs Percentage Of GDP, 2012 - 2020; 11.5.6 France Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 11.6 Australia Oncology Drugs Market; 11.6.1 Australia Oncology Drugs Market Overview; 11.6.2 Australia Oncology Drugs Historic Market, 2012 - 2016; 11.6.3 Australia Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.6.6 Australia Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 11.7. China Oncology Drugs Market; 11.7.1. China Oncology Drugs Market Overview; 11.7.2 China Oncology Drugs Historic Market, 2012 - 2016; 11.7.3 China Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.7.7 China Per Capita Average Oncology Drugs Expenditure, 2012 - 2020; 11.8 Japan Oncology Drugs Market; 11.8.1. Japan Oncology Drugs Market Overview; 11.8.2 Japan Oncology Drugs Historic Market, 2012 - 2016; 11.8.3 Japan Oncology Drugs Market, 2016, By Segment; Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Non-Small Cell Lung Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma); 11.8.8 Japan Per Capita Average Oncology Drugs Expenditure, 2012 - 2020;

Table 1: Global Oncology Drugs Historic Market Growth
Table 2: Global Oncology Drugs Forecast Market Growth
Table 3: Oncology Drugs Market Segmentation
Table 4: Global Oncology Drugs Market, 2016, By Segment
Table 5: Global Oncology Drugs Market, 2012 - 2020, Historic And Forecast, By Segment
Table 6: Global Oncology Drugs Market, 2016, By Region
Table 7: Global Oncology Drugs Market, 2012 - 2020, Historic And Forecast, By Region
Table 8: Oncology Drugs Market, 2016, By Country
Table 9: Oncology Drugs Market, 2012 - 2020, Historic And Forecast, By Country
Table 10: Oncology Drugs Market Size, Percentage Of GDP, Global
Table 11: Per Capita Average Oncology Drugs Expenditure, Global
Table 12: Oncology Drugs Market Comparison With Macro Economic Factors Across Countries
Table 13: Oncology Drugs Market Size, Percentage Of GDP, By Country
Table 14: Per Capita Average Oncology Drugs Expenditure, By Country
Table 15: Global Number Of Pharmacists, 2016, By Country
Table 16: Global Oncology Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country
Table 17: Global Number Of Pharma Enterprises, 2016, By Country
Table 18: Global Oncology Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country
Table 19: Global Average Spending On R&D/Product Development, 2016, By Country
Table 20: Global Oncology Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country
Table 21: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Table 22: Global Oncology Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Table 23: Prevalent Cases Of Cancer, 2016, By Country

Table 24: Asia-Pacific Oncology Drugs Historic Market, 2012 - 2016

Table 25: Asia-Pacific Oncology Drugs Forecast Market, 2016 - 2020

Table 26: Asia-Pacific Oncology Drugs Market, 2016, By Segment

Table 27: China Oncology Drugs Historic Market, 2012 - 2016

Table 28: China Oncology Drugs Forecast Market, 2016 - 2020

Table 29: China Oncology Drugs Market, 2016, By Segment

Table 30: China Oncology Drugs Percentage Of GDP, 2012 - 2020

Table 31: China Per Capita Average Oncology Drugs Expenditure, 2012 - 2020

Table 32: India Oncology Drugs Historic Market, 2012 - 2016

Table 33: India Oncology Drugs Forecast Market, 2016 - 2020

Table 34: India Oncology Drugs Market, 2016, By Segment

Table 35: India Oncology Drugs Percentage Of GDP, 2012 - 2020

Table 36: India Per Capita Average Oncology Drugs Expenditure, 2012 - 2020

Table 37: Japan Oncology Drugs Historic Market, 2012 - 2016

Table 38: Japan Oncology Drugs Forecast Market, 2016 - 2020

Table 39: Japan Oncology Drugs Market, 2016, By Segment

Table 40: Japan Oncology Drugs Percentage Of GDP, 2012 - 2020

Table 41: Japan Per Capita Average Oncology Drugs Expenditure, 2012 - 2020

Table 42: Australia Oncology Drugs Historic Market, 2012 - 2016

Table 43: Australia Oncology Drugs Forecast Market, 2016 - 2020

Table 44: Australia Oncology Drugs Market, 2016, By Segment

Table 45: Australia Oncology Drugs Percentage Of GDP, 2012 - 2020

Table 46: Australia Per Capita Average Oncology Drugs Expenditure, 2012 - 2020

Table 47: Western Europe Oncology Drugs Historic Market, 2012 - 2016

Table 48: Western Europe Oncology Drugs Forecast Market, 2016 - 2020

Table 49: Western Europe Oncology Drugs Market, 2016, By Segment

Table 50: UK Oncology Drugs Historic Market, 2012 - 2016
Table 51: UK Oncology Drugs Forecast Market, 2016 - 2020
Table 52: UK Oncology Drugs Market, 2016, By Segment
Table 53: UK Oncology Drugs Percentage Of GDP, 2012 - 2020
Table 54: UK Per Capita Average Oncology Drugs Expenditure, 2012 - 2020
Table 55: Germany Oncology Drugs Historic Market, 2012 - 2016
Table 56: Germany Oncology Drugs Forecast Market, 2016 - 2020
Table 57: Germany Oncology Drugs Market, 2016, By Segment
Table 58: Germany Oncology Drugs Percentage Of GDP, 2012 - 2020
Table 59: Germany Per Capita Average Oncology Drugs Expenditure, 2012 - 2020
Table 60: France Oncology Drugs Historic Market, 2012 - 2016
Table 61: France Oncology Drugs Forecast Market, 2016 - 2020
Table 62: France Oncology Drugs Market, 2016, By Segment
Table 63: France Oncology Drugs Percentage Of GDP, 2012 - 2020
Table 64: France Per Capita Average Oncology Drugs Expenditure, 2012 - 2020
Table 65: Italy Oncology Drugs Historic Market, 2012 - 2016
Table 66: Italy Oncology Drugs Forecast Market, 2016 - 2020
Table 67: Italy Oncology Drugs Market, 2016, By Segment
Table 68: Italy Oncology Drugs Percentage Of GDP, 2012 - 2020
Table 69: Italy Per Capita Average Oncology Drugs Expenditure, 2012 - 2020
Table 70: Spain Oncology Drugs Historic Market, 2012 - 2016
Table 71: Spain Oncology Drugs Forecast Market, 2016 - 2020
Table 72: Spain Oncology Drugs Market, 2016, By Segment
Table 73: Spain Oncology Drugs Percentage Of GDP, 2012 - 2020
Table 74: Spain Per Capita Average Oncology Drugs Expenditure, 2012 - 2020
Table 75: Eastern Europe Oncology Drugs Historic Market, 2012 - 2016
Table 76: Eastern Europe Oncology Drugs Forecast Market, 2016 - 2020
Table 77: Eastern Europe Oncology Drugs Market, 2016, By Segment
Table 78: Russia Oncology Drugs Historic Market, 2012 - 2016
Table 79: Russia Oncology Drugs Forecast Market, 2016 - 2020
Table 80: Russia Oncology Drugs Market, 2016, By Segment
Table 81: Russia Oncology Drugs Percentage Of GDP, 2012 - 2020
Table 82: Russia Per Capita Average Oncology Drugs Expenditure, 2012 - 2020
Table 83: North America Oncology Drugs Historic Market, 2012 - 2016
Table 84: North America Oncology Drugs Forecast Market, 2016 - 2020
Table 85: North America Oncology Drugs Market, 2016, By Segment
Table 86: USA Oncology Drugs Historic Market, 2012 - 2016
Table 87: USA Oncology Drugs Forecast Market, 2016 - 2020
Table 88: USA Oncology Drugs Market, 2016, By Segment
Table 89: USA Oncology Drugs Percentage Of GDP, 2012 - 2020
Table 90: USA Per Capita Average Oncology Drugs Expenditure, 2012 - 2020
Table 91: South America Oncology Drugs Historic Market, 2012 - 2016
Table 92: South America Oncology Drugs Forecast Market, 2016 - 2020
Table 93: South America Oncology Drugs Market, 2016, By Segment
Table 94: Brazil Oncology Drugs Historic Market, 2012 - 2016
Table 95: Brazil Oncology Drugs Forecast Market, 2016 - 2020
Table 96: Brazil Oncology Drugs Market, 2016, By Segment
Table 97: Brazil Oncology Drugs Percentage Of GDP, 2012 - 2020
Table 98: Brazil Per Capita Average Oncology Drugs Expenditure, 2012 - 2020
Table 99: Middle East Oncology Drugs Historic Market, 2012 - 2016
Table 100: Middle East Oncology Drugs Forecast Market, 2016 - 2020
Table 101: Middle East Oncology Drugs Market, 2016, By Segment
Table 102: Africa Oncology Drugs Historic Market, 2012 - 2016
Table 103: Africa Oncology Drugs Forecast Market, 2016 - 2020
Table 104: Africa Oncology Drugs Market, 2016, By Segment
Table 105: F. Hoffmann-La Roche Ltd Financial Performance
Table 106: Novartis Ag Financial Performance
Table 107: Celgene Financial Performance
Table 108: Johnson & Johnson Financial Performance
Table 109: Bristol-Myers Squibb Company Financial Performance
Table 110: Pharmaceutical Drugs Market Historic Growth
Table 111: Pharmaceutical Drugs Market Forecast Growth
Table 112: Global Pharmaceutical Drugs Market, 2016, By Region
Table 113: Global Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Region
Table 114: Pharmaceutical Drugs Market, 2016, By Country
Table 115: Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Country
Table 116: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment
Table 117: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment
Table 118: Pharmaceutical Drugs Market Size, Percentage Of GDP, Global
Table 119: Per Capita Average Pharmaceutical Drugs Expenditure, Global
Table 120: Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries
Table 121: Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country
Table 122: Per Capita Average Pharmaceutical Drugs Expenditure, By Country
Table 123: Pharmaceuticals Industry Financial Margins

Figure 1: Global Oncology Drugs Historic Market Growth
Figure 2: Global Oncology Drugs Forecast Market Growth
Figure 3: Oncology Drugs Market Segmentation
Figure 4: Global Oncology Drugs Market, 2016, By Segment
Figure 5: Global Oncology Drugs Market, 2012 - 2020, Historic And Forecast, By Segment
Figure 6: Global Oncology Drugs Market, 2016, By Region
Figure 7: Global Oncology Drugs Market, 2012 - 2020, Historic And Forecast, By Region
Figure 8: Oncology Drugs Market, 2016, By Country
Figure 9: Oncology Drugs Market, 2012 - 2020, Historic And Forecast, By Country
Figure 10: Oncology Drugs Market Size, Percentage Of GDP, Global
Figure 11: Per Capita Average Oncology Drugs Expenditure, Global
Figure 12: Oncology Drugs Market Comparison With Macro Economic Factors Across Countries
Figure 13: Oncology Drugs Market Size, Percentage Of GDP, By Country
Figure 14: Per Capita Average Oncology Drugs Expenditure, By Country
Figure 15: Global Number Of Pharmacists, 2016, By Country
Figure 16: Global Oncology Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country
Figure 17: Global Number Of Pharma Enterprises, 2016, By Country
Figure 18: Global Oncology Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country
Figure 19: Global Average Spending On R&D/Product Development, 2016, By Country
Figure 20: Global Oncology Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country

Figure 21: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Figure 22: Global Oncology Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Figure 23: Prevalent Cases Of Cancer, 2016, By Country

Figure 24: Asia-Pacific Oncology Drugs Historic Market, 2012 - 2016

Figure 25: Asia-Pacific Oncology Drugs Forecast Market, 2016 - 2020

Figure 26: Asia-Pacific Oncology Drugs Market, 2016, By Segment

Figure 27: China Oncology Drugs Historic Market, 2012 - 2016

Figure 28: China Oncology Drugs Forecast Market, 2016 - 2020

Figure 29: China Oncology Drugs Market, 2016, By Segment

Figure 30: China Oncology Drugs Percentage Of GDP, 2012 - 2020

Figure 31: China Per Capita Average Oncology Drugs Expenditure, 2012 - 2020

Figure 32: India Oncology Drugs Historic Market, 2012 - 2016

Figure 33: India Oncology Drugs Forecast Market, 2016 - 2020

Figure 34: India Oncology Drugs Market, 2016, By Segment

Figure 35: India Oncology Drugs Percentage Of GDP, 2012 - 2020

Figure 36: India Per Capita Average Oncology Drugs Expenditure, 2012 - 2020

Figure 37: Japan Oncology Drugs Historic Market, 2012 - 2016

Figure 38: Japan Oncology Drugs Forecast Market, 2016 - 2020

Figure 39: Japan Oncology Drugs Market, 2016, By Segment

Figure 40: Japan Oncology Drugs Percentage Of GDP, 2012 - 2020

Figure 41: Japan Per Capita Average Oncology Drugs Expenditure, 2012 - 2020

Figure 42: Australia Oncology Drugs Historic Market, 2012 - 2016

Figure 43: Australia Oncology Drugs Forecast Market, 2016 - 2020

Figure 44: Australia Oncology Drugs Market, 2016, By Segment

Figure 45: Australia Oncology Drugs Percentage Of GDP, 2012 - 2020

Figure 46: Australia Per Capita Average Oncology Drugs Expenditure, 2012 - 2020

Figure 47: Western Europe Oncology Drugs Historic Market, 2012 - 2016

Figure 48: Western Europe Oncology Drugs Forecast Market, 2016 - 2020

Figure 49: Western Europe Oncology Drugs Market, 2016, By Segment
Figure 81: Russia Oncology Drugs Percentage Of GDP, 2012 - 2020
Figure 82: Russia Per Capita Average Oncology Drugs Expenditure, 2012 - 2020
Figure 83: North America Oncology Drugs Historic Market, 2012 - 2016
Figure 84: North America Oncology Drugs Forecast Market, 2016 - 2020
Figure 85: North America Oncology Drugs Market, 2016, By Segment
Figure 86: USA Oncology Drugs Historic Market, 2012 - 2016
Figure 87: USA Oncology Drugs Forecast Market, 2016 - 2020
Figure 88: USA Oncology Drugs Market, 2016, By Segment
Figure 89: USA Oncology Drugs Percentage Of GDP, 2012 - 2020
Figure 90: USA Per Capita Average Oncology Drugs Expenditure, 2012 - 2020
Figure 91: South America Oncology Drugs Historic Market, 2012 - 2016
Figure 92: South America Oncology Drugs Forecast Market, 2016 - 2020
Figure 93: South America Oncology Drugs Market, 2016, By Segment
Figure 94: Brazil Oncology Drugs Historic Market, 2012 - 2016
Figure 95: Brazil Oncology Drugs Forecast Market, 2016 - 2020
Figure 96: Brazil Oncology Drugs Market, 2016, By Segment
Figure 97: Brazil Oncology Drugs Percentage Of GDP, 2012 - 2020
Figure 98: Brazil Per Capita Average Oncology Drugs Expenditure, 2012 - 2020
Figure 99: Middle East Oncology Drugs Historic Market, 2012 - 2016
Figure 100: Middle East Oncology Drugs Forecast Market, 2016 - 2020
Figure 101: Middle East Oncology Drugs Market, 2016, By Segment
Figure 102: Africa Oncology Drugs Historic Market, 2012 - 2016
Figure 103: Africa Oncology Drugs Forecast Market, 2016 - 2020
Figure 104: Africa Oncology Drugs Market, 2016, By Segment
Figure 105: F. Hoffmann-La Roche Ltd Financial Performance
Figure 106: Novartis Ag Financial Performance
Figure 107: Celgene Financial Performance
Figure 108: Johnson & Johnson Financial Performance
Figure 109: Bristol-Myers Squibb Company Financial Performance
Figure 110: Pharmaceutical Drugs Market Historic Growth
Figure 111: Pharmaceutical Drugs Market Forecast Growth
Figure 112: Global Pharmaceutical Drugs Market, 2016, By Region
Figure 113: Global Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Region
Figure 114: Pharmaceutical Drugs Market, 2016, By Country
Figure 115: Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Country
Figure 116: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment
Figure 117: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment
Figure 118: Pharmaceutical Drugs Market Size, Percentage Of GDP, Global
Figure 119: Per Capita Average Pharmaceutical Drugs Expenditure, Global
Figure 120: Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries
Figure 121: Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country
Figure 122: Per Capita Average Pharmaceutical Drugs Expenditure, By Country
Figure 123: Pharmaceuticals Industry Financial Margins
How to Buy...


Option 1 - Online
Go to our website and pay online with any major debit or credit card:
https://www.bioportfolio.co.uk/product/109260

Option 2 - Request a Proforma Invoice
Fill in the details below, and either Scan this page and email it to us at pdb@bioportfolio.co.uk or Fax it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name: 
Job Title: 
Your Email: 
Your Contact Phone: 
Company Name: 
Address: 
Post/Zip Code: 
Country: 
P.O. Number: 
Any Other Instructions: 

Pricing Options: (please tick one)
- &amp;#36;4000 | Single User Price
- &amp;#36;6000 | Site License Price
- &amp;#36;8000 | Enterprise License Price

Payment Options: (please tick one)
- Online Credit Card (we will email you the invoice with a payment link)
- Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature: 

Option 3 - Phone Us on +44 (0)7887 945155
We will be delighted to give you our personal attention.